The company’s focus on expanding its presence in the Type 2 diabetes market and introducing new products like the Mobi pump platform is expected to drive future growth. Tandem’s gross margin for 2024 ...

U.Today - Mike McGlone, the senior commodity strategist at Bloomberg Intelligence, has taken to his social media account to share his take on the prospects the markets are likely... XRP Hits Wall ...

The company's focus on expanding its presence in the Type 2 diabetes market and introducing new products like the Mobi pump platform is expected to drive future growth. Tandem's gross margin for ...

The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other ...

Tandem Diabetes Care Inc. (NASDAQ:TNDM) reported a positive earnings surprise for Q4 2024, with an EPS of $0.01 against a forecast of -$0.21. The company’s revenue also exceeded expectations, reaching ...

The next-generation Control-IQ+ algorithm, used to enable automated insulin delivery (AID) in conjunction with Tandem’s t:slim X2 and Mobi insulin pumps, was already approved for people with ...

Their NOPAT increases over time, while invested capital grows minimally. This isn't exactly the case with CME. Their margins are nothing short of excellent. You might notice that ROE and ROIC are ...

CME Group enjoyed favorable market conditions in 2024 as volatility across multiple asset classes drove increased trading volume, leading to strong revenue growth. Before 2023, the most ...